Social Anxiety Treatment

Medication for Social Anxiety

Medication can reduce social anxiety symptoms for some adults, particularly when fear is broad, persistent, or accompanied by depression or another anxiety disorder. The most established medication options are certain antidepressants, especially SSRIs and the SNRI venlafaxine.

Medication is not necessary for everyone, does not replace social learning, and can cause adverse effects. The choice requires an individualized discussion with a qualified prescriber about evidence, health history, other medications and substances, pregnancy considerations, monitoring, personal preference, and alternatives.

Short Answer

SSRIs and SNRIs have the strongest medication evidence for adult social anxiety disorder. NICE recommends individual CBT specifically developed for social anxiety as the initial adult treatment; if an adult declines cognitive behavioral treatment and prefers medication, the UK guideline recommends discussing an SSRI. Other guidelines, approvals, and available drugs vary by country.

These medications are usually taken regularly rather than only before a social event. Benefits develop gradually, response varies, and early adverse effects may appear before improvement. Prescribing should include informed consent, an interaction and safety review, a monitoring plan, and guidance for missed doses and eventual discontinuation.

This page cannot tell you which medication to take. Drug choice and dosing depend on factors that cannot be assessed safely in a general article. Do not start, borrow, combine, increase, reduce, or stop prescription medication without advice from an appropriately qualified prescriber.

Evidence Snapshot

Evidence category: Established for several adult antidepressant options.

Randomized trials, systematic reviews, and network meta-analyses support pharmacological treatment for adult social anxiety disorder. SSRIs have the most consistent evidence across medications, and venlafaxine has supportive evidence among SNRIs. Medication can reduce clinician-rated and self-reported symptoms, but not everyone responds and trial averages do not predict individual benefit or tolerability.

Comparative evidence generally supports disorder-specific CBT as a leading initial treatment for adults. Medication remains a legitimate evidence-based option when preferred, when CBT is unavailable, after an insufficient response, or when the clinical picture supports it. The decision is not a contest between “natural” and “medical” care; it is a comparison of likely benefits, burdens, uncertainty, access, and goals.

Evidence is more limited for later-line drugs, augmentation strategies, optimal sequencing, and long-term outcomes. Published trials may underrepresent complex comorbidity, pregnancy, older adults, medically unwell people, and groups facing barriers or discrimination. Guideline recommendations should therefore be combined with individualized care.

For a broader comparison, see Treatment for Social Anxiety and Evidence Standards.

What Medication May—and May Not—Change

When effective, medication may reduce:

  • anticipatory anxiety before social or performance situations;
  • overall social fear and distress;
  • physical arousal and panic-like symptoms;
  • the pressure to avoid, escape, or use substances to cope;
  • co-occurring depressive or other anxiety symptoms, depending on the medication and diagnosis.

Symptom relief may make it easier to attend therapy, practice exposure, work, study, connect, or rest. But medication does not directly teach assertiveness, conversation, attention shifting, boundary setting, relationship skills, or how to interpret a social setback. It does not automatically change safety behaviors, shame, perfectionism, rumination, or beliefs about judgment.

Medication also cannot correct a hostile workplace, bullying, abuse, discrimination, isolation, poverty, or an inaccessible environment. Reducing symptoms should not be used to make a person tolerate genuine harm.

Established Medication Options for Adults

Selective serotonin reuptake inhibitors (SSRIs)

SSRIs are antidepressants also used for anxiety disorders. Being offered one does not mean that a clinician thinks social anxiety is “just depression.” Several SSRIs have evidence for social anxiety disorder, but licensed indications and usual choices differ across countries.

In its UK pathway, NICE names escitalopram or sertraline when an adult chooses medication after declining cognitive behavioral treatment. If these do not help or cannot be tolerated, it lists other options later in the sequence. This is a specific guideline pathway—not a universal instruction or a statement that the named drugs suit every person.

Serotonin–norepinephrine reuptake inhibitors (SNRIs)

Venlafaxine is the SNRI with an established social anxiety evidence base and appears in NICE as an alternative after nonresponse or intolerance to initial SSRI options. SNRIs share some adverse effects with SSRIs and may have additional considerations such as blood-pressure or heart-rate effects. Venlafaxine is also associated with potentially significant discontinuation symptoms.

There is no universally “best” antidepressant

Selection may consider previous personal or family response, other diagnoses, sleep and energy, sexual and gastrointestinal effects, weight concerns, cardiovascular and bleeding risks, pregnancy or breastfeeding, interactions, overdose toxicity, discontinuation risk, availability, cost, and the person’s priorities. A prescriber should explain why a particular option is being suggested.

Other Medication Classes

Monoamine oxidase inhibitors (MAOIs)

Some MAOIs, particularly phenelzine, have evidence for social anxiety disorder. They are generally specialist, later-line options because of adverse effects, potentially serious food and drug interactions, washout requirements, and—in the case of irreversible MAOIs—strict safety precautions. Moclobemide, a reversible inhibitor of monoamine oxidase A, is available in some countries but not others and has shown less consistent benefit.

MAOIs must not be combined casually with antidepressants, stimulants, decongestants, certain pain medicines, recreational drugs, supplements, or many other agents. Dietary and medication restrictions must come directly from the prescriber and pharmacist.

Beta-blockers

Beta-blockers such as propranolol are sometimes prescribed off-label to reduce physical symptoms in circumscribed performance situations. They are not established treatments for the broader pattern of social anxiety disorder. A 2025 systematic review found no robust evidence of benefit for anxiety disorders, including social phobia, although the included evidence was small and methodologically limited.

Beta-blockers can lower heart rate and blood pressure and may be unsuitable with asthma or some respiratory, cardiovascular, metabolic, or circulation conditions. They can also interact with other medication. “Only for a presentation” does not make unsupervised use safe.

Benzodiazepines

Some benzodiazepines have shown short-term anxiolytic effects, but NICE advises against routinely offering them for adult social anxiety disorder. Risks can include sedation, impaired attention and memory, slowed reaction time, falls, tolerance, dependence, withdrawal, and dangerous interactions with alcohol, opioids, sleep medication, or other sedatives.

Benzodiazepines may also make it harder to evaluate what was learned during a social task if improvement is attributed entirely to the drug. They should not be borrowed, purchased informally, mixed with substances, or stopped abruptly after regular use without medical guidance; withdrawal can be serious.

Anticonvulsants, tricyclics, antipsychotics, buspirone, and other drugs

Some agents have limited, mixed, or preliminary evidence, but potential benefit must be weighed against adverse-effect burden and better-supported alternatives. NICE advises against routinely offering anticonvulsants, tricyclic antidepressants, or antipsychotic medication specifically for adult social anxiety disorder. A medication may still be prescribed for another diagnosis; that is different from recommending it as routine social anxiety treatment.

St John’s wort, supplements, and over-the-counter products

NICE advises against St John’s wort and other over-the-counter preparations for social anxiety disorder because evidence is lacking and interactions can be significant. St John’s wort can alter the effects of many medicines, including antidepressants, contraceptives, anticoagulants, transplant drugs, seizure medication, and others. “Natural,” “calming,” or available without a prescription does not mean safe, effective, or compatible with treatment.

Before and After Starting Medication

Assessment before prescribing

A prescriber may need to review:

  • the diagnosis, severity, impairment, goals, and previous treatment;
  • depression, self-harm or suicide risk, bipolar or manic symptoms, psychosis, trauma, eating difficulties, and substance use;
  • medical conditions, allergies, blood pressure, heart history, seizures, bleeding risk, liver or kidney concerns, and other relevant health factors;
  • all prescription drugs, nonprescription products, supplements, caffeine or stimulants, alcohol, cannabis, and recreational substances;
  • previous adverse effects, discontinuation experiences, and personal or family medication response;
  • pregnancy, trying to conceive, fertility priorities, breastfeeding, and sexual health;
  • overdose risk, capacity for safe storage, and the monitoring support available.

Not every person needs the same physical examination or tests. The prescriber should explain what is indicated and why.

Informed consent

You should receive understandable information about expected benefits, common and important adverse effects, interactions, early activation, likely timing, monitoring, alternatives, what to do if symptoms worsen, and how medication would eventually be reduced. Ask whether the use is licensed for social anxiety in your country or off-label and what that means.

Early monitoring

Adverse effects can begin before therapeutic benefit. NICE recommends follow-up soon after an SSRI or SNRI is started and closer early monitoring for people under 30 because antidepressants are associated with increased suicidal thinking and self-harm in a minority of younger people. Anyone assessed as having suicide risk needs close follow-up regardless of age. Local guidance may differ, but a clear safety plan should not be optional.

How long until it helps?

Benefit is gradual rather than immediate. NICE notes that the anxiolytic effect develops over two weeks or more, while its partial-response decision point for an initial SSRI is after 10–12 weeks. These statements do not mean everyone should wait that long despite severe adverse effects, nor that no one improves earlier. Timing depends on the drug, dose, adherence, tolerability, and clinical situation and should be reviewed by the prescriber.

Adverse Effects and Safety

Adverse effects vary by medication and person. Some are mild and temporary; others are persistent, unacceptable, or medically important. A balanced discussion should neither minimize them nor imply that everyone will experience them.

SSRIs and SNRIs may be associated with:

  • nausea, diarrhea, constipation, appetite changes, or other gastrointestinal symptoms;
  • headache, dizziness, sweating, dry mouth, or fatigue;
  • sleepiness, insomnia, vivid dreams, agitation, or restlessness;
  • increased anxiety or jitteriness early in treatment;
  • sexual effects such as reduced desire, arousal difficulties, erectile difficulties, delayed orgasm, or inability to orgasm;
  • emotional blunting or feeling less emotionally responsive;
  • weight change over time;
  • blood-pressure or heart-rate effects, particularly with some SNRIs;
  • discontinuation symptoms if doses are missed or treatment is reduced too quickly.

Less common but serious problems can occur, including severe allergic reactions, serotonin toxicity, clinically significant bleeding, low sodium, seizures, dangerous rhythm effects with susceptible people or interacting drugs, and mania or hypomania in people vulnerable to bipolar disorder. The relevant risks differ substantially by medication and health history.

When to get urgent help

Follow the medication information and prescriber’s emergency instructions. Seek urgent medical help for signs of a severe allergic reaction, severe confusion or agitation with fever and muscle symptoms, fainting, a seizure, severe chest symptoms, rapidly escalating mania, or other alarming physical or mental changes. New or worsening suicidal thoughts, self-harm urges, or inability to stay safe require immediate support.

Do not silently tolerate unacceptable effects

Sexual effects, emotional blunting, weight changes, fatigue, and other quality-of-life concerns are legitimate treatment outcomes. Tell the prescriber. Options may include monitoring, changing timing or dose, switching treatment, or another strategy—but these decisions require clinical guidance.

Interactions, Alcohol, and Other Substances

Give the prescriber and pharmacist a complete list of everything you take, including products used only occasionally. Interaction risk can involve antidepressants, MAOIs, benzodiazepines, beta-blockers, pain medicines, migraine medicines, cold remedies, stimulants, sleep aids, anticoagulants, antibiotics, supplements, and recreational substances.

Alcohol can worsen anxiety, sleep, depression, judgment, and medication adverse effects. Combining alcohol with benzodiazepines, opioids, or other sedating medication can be especially dangerous. Cannabis and other substances can also alter anxiety, cognition, heart rate, sedation, motivation, or psychosis risk and make treatment response harder to interpret.

Substance use may be an attempt to cope with social anxiety and should be discussed without shame. It does not automatically exclude social anxiety treatment, but dependence, withdrawal, overdose risk, or hazardous use may require additional or coordinated care. Do not conceal substance use from a prescriber out of fear of judgment; the information can be essential for safety.

How to Know Whether Medication Is Helping

“I feel different” is important but incomplete. Before starting, identify target symptoms and functional goals. Progress might include:

  • less anticipatory dread or physical arousal;
  • entering situations that were previously avoided;
  • staying engaged longer and relying less on alcohol or reassurance;
  • participating more at work, school, appointments, or in relationships;
  • recovering more easily after social stress;
  • improvement in co-occurring depression or another anxiety condition;
  • benefits that outweigh adverse effects according to the person’s priorities.

Validated measures such as the SPIN or LSAS may help track symptoms, but functioning, quality of life, adverse effects, and personal goals also matter. Improvement caused by avoiding more situations is not meaningful treatment success.

Partial response

A partial response may justify more time, adjustment, adding disorder-specific CBT, or another plan depending on tolerability and clinical judgment. NICE recommends adding individual CBT after only a partial response to an initial SSRI trial, and considering medication alongside CBT after a partial response to an adequate CBT course.

No response or poor tolerability

The prescriber may review diagnosis, adherence, duration, dose, interactions, substance use, medical contributors, and co-occurring conditions before recommending a switch or later-line option. Do not increase the dose or combine agents independently. Repeated medication changes without a clear review can expose you to risk without answering why treatment is not helping.

Worsening

Contact the prescriber promptly if anxiety, agitation, insomnia, impulsivity, mood instability, suicidal thinking, or other symptoms worsen. Urgency depends on severity; immediate danger requires emergency or crisis help rather than waiting for a routine appointment.

How Long to Continue—and How to Stop

After a good response, continuing medication for a period can reduce relapse risk. NICE recommends continuing an effective medication for at least a further six months after a good response in the first three months. The appropriate duration may be longer or shorter depending on recurrence, residual symptoms, adverse effects, life circumstances, therapy progress, and preference.

Discontinuation is not the same as addiction

SSRIs and SNRIs are not considered addictive in the way benzodiazepines, opioids, or some recreational drugs can be. However, the nervous system adapts to them, and reducing too quickly can cause discontinuation symptoms. Physical dependence in this sense is real even without craving, intoxication, or compulsive use.

Discontinuation symptoms may include:

  • dizziness, imbalance, nausea, flu-like sensations, or sweating;
  • sleep disturbance, vivid dreams, fatigue, or headache;
  • anxiety, irritability, low mood, agitation, or tearfulness;
  • unusual sensory experiences sometimes described as electric-shock sensations;
  • other symptoms depending on the medication and rate of reduction.

Discontinuation can be confused with relapse, and both can occur. Timing, symptom pattern, response to reinstatement, and clinical history may help distinguish them, but the assessment is not always simple.

Taper with the prescriber

NICE advises reducing medication gradually. The plan may need to be slower for long-term use, higher doses, medications with shorter half-lives, previous withdrawal difficulty, or emerging symptoms. There is no single taper schedule appropriate for every person. If symptoms occur, contact the prescriber rather than alternating doses, skipping unpredictably, or improvising with formulations.

If you miss a dose, follow the official patient information or instructions from your prescriber or pharmacist. Do not automatically double the next dose.

Medication and Psychological Treatment

Medication and therapy work through partly different routes. Medication may reduce symptom intensity. Disorder-specific CBT creates direct learning about predictions, attention, avoidance, safety behaviors, imagery, and rumination. A person may prefer either treatment, use them sequentially, or combine them after shared decision-making.

Combination is not automatically necessary or superior for every person. It may add cost, adverse effects, and complexity. NICE specifically suggests combination after partial response rather than recommending both treatments routinely from the start for all adults.

Medication does not invalidate behavioral experiments or exposure. The useful question is whether a person can engage and learn, not whether anxiety is completely unmedicated. If someone believes “I coped only because of the pill,” therapy can examine that interpretation carefully without demanding unsafe medication changes.

Never reduce medication to make an exposure “more authentic” unless the prescriber has independently recommended and supervised the change.

Special Considerations

Children and young people

NICE recommends social-anxiety-focused individual or group CBT for children and young people and advises against routinely offering medication specifically for social anxiety disorder in this age group. Medication may be considered for other or complex clinical reasons under specialist care, but adult pathways should not be copied onto minors. Antidepressant treatment in younger people requires careful monitoring for suicidal thinking and behavioral changes.

Pregnancy, trying to conceive, and breastfeeding

Discuss plans early with the prescriber and the relevant obstetric or perinatal clinician. Both untreated illness and medication exposure can carry risks, and those risks vary by drug, timing, dose, health, and individual history. Do not stop abruptly after discovering a pregnancy; obtain individualized advice. Fertility and sexual adverse effects may also matter before conception.

Bipolar disorder and mood elevation

Antidepressants can contribute to mania or hypomania in susceptible people. Tell the clinician about periods of unusually elevated or irritable mood, greatly reduced need for sleep, racing thoughts, impulsive or risky behavior, psychosis, and personal or family bipolar history. Rapid mood elevation after starting treatment requires prompt clinical review.

Older adults and medical comorbidity

Falls, low sodium, bleeding, heart rhythm, blood pressure, kidney or liver function, cognitive effects, and multiple drug interactions may require additional caution. Age alone does not rule out treatment, but the monitoring and preferred options may differ.

Neurodivergence and disability

Medication may reduce co-occurring anxiety but should not be used to erase autistic traits, communication differences, sensory needs, or disability-related self-advocacy. Assessment should distinguish social fear from sensory overload, masking, misunderstanding, trauma, and genuine accessibility barriers.

Driving, work, and safety-sensitive activities

Sedation, dizziness, slowed reaction time, blurred vision, agitation, or impaired concentration can affect driving, machinery, heights, clinical duties, and other safety-sensitive tasks. Follow local law, official medication warnings, and prescriber or pharmacist advice—especially when starting, changing, or combining medication.

Questions to Ask a Prescriber

  • What diagnosis and target symptoms is this medication intended to address?
  • Why are you suggesting this option rather than CBT, another medication, or watchful waiting?
  • Is it licensed for social anxiety disorder in this country, or is the use off-label?
  • What benefits are realistic, and when should we review whether it is helping?
  • Which common, serious, sexual, emotional, weight, sleep, and discontinuation effects should I know about?
  • Could it interact with my prescriptions, supplements, contraception, alcohol, cannabis, caffeine, or other substances?
  • Do my medical history, pregnancy plans, age, bipolar risk, or other diagnoses change the choice?
  • What symptoms require a routine call, urgent assessment, or emergency help?
  • How often will follow-up occur, and how will symptoms, functioning, adverse effects, and suicide risk be monitored?
  • What should I do if I miss a dose?
  • If it works, how long might I continue it?
  • What would a supervised taper involve, and what is the plan if discontinuation symptoms occur?
  • What is the next step after partial benefit, no benefit, or unacceptable adverse effects?

A prescriber should welcome informed questions and explain uncertainty. If access is brief, bring a written medication list and the three or four questions most important to you.

When More Immediate Help Is Needed

Contact a clinician promptly for significant worsening, severe adverse effects, escalating agitation or insomnia, signs of mania, new suicidal thoughts, dangerous substance combinations, or difficulty stopping a medication. Suspected overdose, severe reaction, or immediate danger requires emergency medical help.

If you may harm yourself or someone else, cannot stay safe, or are in immediate danger, contact local emergency services or an appropriate crisis service now. Use this site’s crisis help page to find options.

Key Takeaways

  • SSRIs and the SNRI venlafaxine have the most established medication evidence for adult social anxiety disorder.
  • Specific drug choices, approvals, and treatment sequences vary by country and individual health factors.
  • Benefits develop gradually, while adverse effects can appear early; planned monitoring is essential.
  • Sexual effects, emotional blunting, sleep, weight, and quality of life are legitimate parts of evaluating treatment.
  • Beta-blockers are not established general treatments for social anxiety disorder, and benzodiazepines are not routinely recommended by NICE.
  • MAOIs are later-line specialist options with important food, drug, and washout precautions.
  • Medication can reduce symptoms but does not directly teach the learning and interpersonal changes targeted by CBT.
  • Do not combine, borrow, stop, or alter medication without qualified advice; discontinuation symptoms are real and tapering must be individualized.
  • Children, pregnancy, bipolar risk, substance use, older age, medical illness, and multiple medications require additional assessment.

Continue Learning

These pages place medication within the wider treatment and decision-making context.

Treatment for Social Anxiety

Compare medication, CBT, other therapies, treatment formats, and next-step decisions.

CBT for Social Anxiety

Learn what disorder-specific CBT involves, how it works, and how to assess therapist competence.

Exposure Therapy

Understand how planned approach practice creates learning without requiring medication changes.

How to Choose a Therapist

Evaluate professional credentials, social-anxiety competence, fit, planning, and red flags.

Evidence Standards

See how CSA evaluates treatment research and communicates certainty and limitations.

References

Archer, C., Wiles, N., Kessler, D., Turner, K., & Caldwell, D. M. (2025). Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis. Journal of Affective Disorders, 368, 90–99. https://doi.org/10.1016/j.jad.2024.09.068

Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013). The evidence-based pharmacotherapy of social anxiety disorder. International Journal of Neuropsychopharmacology, 16(1), 235–249. https://doi.org/10.1017/S1461145712000119

Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K. M., Clark, D. M., Ades, A. E., & Pilling, S. (2014). Psychological and pharmacological interventions for social anxiety disorder in adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 1(5), 368–376. https://doi.org/10.1016/S2215-0366(14)70329-3

Mitsui, N., Fujii, Y., Asakura, S., et al. (2022). Antidepressants for social anxiety disorder: A systematic review and meta-analysis. Neuropsychopharmacology Reports, 42(4), 398–409. https://doi.org/10.1002/npr2.12275

National Institute for Health and Care Excellence. (2013). Social anxiety disorder: Recognition, assessment and treatment (CG159). https://www.nice.org.uk/guidance/cg159

CSA provides educational information—not individual medical advice, prescribing, diagnosis, treatment, emergency support, or a substitute for professional care. Medication decisions must be made with an appropriately qualified prescriber who can assess your health, other medications and substances, preferences, and risks. Do not start, borrow, combine, increase, reduce, or stop medication based on this page.

If you may have taken an overdose, are experiencing a severe reaction, may harm yourself or someone else, or are otherwise in immediate danger, contact local emergency services or an appropriate crisis or poison service without delay. For more information, see Crisis Help and the Medical and Mental Health Disclaimer.